CureVac Delisted Following BioNTech Acquisition Completion
05.02.2026 - 03:13:05 | boerse-global.de
The chapter for CureVac as an independent publicly traded company has officially closed. The biotech firm’s shares have been removed from the Nasdaq exchange and trading has ceased, marking its full absorption into rival BioNTech. The Tübingen-based company, once a beacon of hope in the sector, has now been integrated into its competitor’s corporate structure.
A complete leadership overhaul accompanied the change in ownership. CureVac’s former executive board resigned en masse. The company’s operations are now directed by BioNTech’s leadership, including CEO Ugur Sahin and COO Sierk Poetting. The primary operational focus is on integration: BioNTech is absorbing CureVac’s research facilities and production capacities in Read more...
So schätzen die Börsenprofis CureVac Aktien ein!
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
Für. Immer. Kostenlos.
NL0015436031 | CUREVAC | boerse | 68552704 |
